| Dr James L Brazil, MD | |
|
424 Lilly Rd Ne, Olympia, WA 98506-5132 | |
| (360) 459-1700 | |
| (360) 459-0537 |
| Full Name | Dr James L Brazil |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 37 Years |
| Location | 424 Lilly Rd Ne, Olympia, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154349421 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207NS0135X | Dermatology - Procedural Dermatology | MD00028815 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ohsu Hospital And Clinics | Portland, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Olympic Dermatology And Laser Clinic P S | 5991791790 | 5 |
News Archive
Nearly 30 percent of outpatient opioid prescriptions in the United States lack documented clinical reasons that justify the use of these potent drugs, according to a national analysis of physician visit records conducted by researchers at Harvard Medical School and the RAND Corporation.
Infants and toddlers who have been treated for cancer tend to reach certain developmental milestones later than do their healthy peers, say researchers at the National Institutes of Health and in Italy.
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
After years of studying the causes of asthma, a pediatrician-turned-public health sleuth thinks there's a way to substantially reduce its impact.
AstraZeneca has announced a $100 million research investment to strategically boost work in the infectious disease area and continue its incremental growth in cancer research at its research center near Boston, Massachusetts.
› Verified 4 days ago
| Entity Name | Olympic Dermatology And Laser Clinic P S |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467470914 PECOS PAC ID: 5991791790 Enrollment ID: O20040426000030 |
News Archive
Nearly 30 percent of outpatient opioid prescriptions in the United States lack documented clinical reasons that justify the use of these potent drugs, according to a national analysis of physician visit records conducted by researchers at Harvard Medical School and the RAND Corporation.
Infants and toddlers who have been treated for cancer tend to reach certain developmental milestones later than do their healthy peers, say researchers at the National Institutes of Health and in Italy.
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
After years of studying the causes of asthma, a pediatrician-turned-public health sleuth thinks there's a way to substantially reduce its impact.
AstraZeneca has announced a $100 million research investment to strategically boost work in the infectious disease area and continue its incremental growth in cancer research at its research center near Boston, Massachusetts.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James L Brazil, MD 424 Lilly Rd Ne, Olympia, WA 98506-5132 Ph: (360) 459-1700 | Dr James L Brazil, MD 424 Lilly Rd Ne, Olympia, WA 98506-5132 Ph: (360) 459-1700 |
News Archive
Nearly 30 percent of outpatient opioid prescriptions in the United States lack documented clinical reasons that justify the use of these potent drugs, according to a national analysis of physician visit records conducted by researchers at Harvard Medical School and the RAND Corporation.
Infants and toddlers who have been treated for cancer tend to reach certain developmental milestones later than do their healthy peers, say researchers at the National Institutes of Health and in Italy.
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
After years of studying the causes of asthma, a pediatrician-turned-public health sleuth thinks there's a way to substantially reduce its impact.
AstraZeneca has announced a $100 million research investment to strategically boost work in the infectious disease area and continue its incremental growth in cancer research at its research center near Boston, Massachusetts.
› Verified 4 days ago
David A Remis, Dermatology Medicare: Not Enrolled in Medicare Practice Location: 700 Lilly Rd Ne, Olympia, WA 98506 Phone: 360-923-7000 | |
Dr. Vivian A Lombillo, MD PHD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 703 Lilly Rd Ne Suite 105, Northwest Pediatric Dermatology, Pllc, Olympia, WA 98506 Phone: 360-539-6141 | |
Shauna M Richert, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 304 W Bay Dr Nw, Suite 301, Olympia, WA 98502 Phone: 360-413-8760 Fax: 360-413-8839 | |
Dr. Kaley Myer, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 304 W Bay Dr Nw Ste 301, Olympia, WA 98502 Phone: 360-413-8760 | |
Dr. Jacob Howard Bauer, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 304 W Bay Dr Nw, Ste 301, Olympia, WA 98502 Phone: 360-413-8760 | |
Dr. James William Young, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 5127 Klahanie Dr Nw, Olympia, WA 98502 Phone: 360-866-4535 |